OLD Point Trust & Financial Services N A Has $4.38 Million Stake in Amgen, Inc. (AMGN)

OLD Point Trust & Financial Services N A cut its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 7.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 25,712 shares of the medical research company’s stock after selling 2,195 shares during the quarter. Amgen makes up approximately 2.5% of OLD Point Trust & Financial Services N A’s portfolio, making the stock its 15th biggest position. OLD Point Trust & Financial Services N A’s holdings in Amgen were worth $4,384,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Kwmg LLC purchased a new stake in Amgen during the second quarter worth approximately $108,000. Mainstay Capital Management LLC ADV purchased a new stake in Amgen during the second quarter worth approximately $111,000. Polaris Greystone Financial Group LLC purchased a new stake in Amgen during the third quarter worth approximately $166,000. Dixon Hubard Feinour & Brown Inc. VA purchased a new stake in Amgen during the second quarter worth approximately $200,000. Finally, Family Firm Inc. purchased a new stake in Amgen during the second quarter worth approximately $202,000. 82.37% of the stock is owned by institutional investors and hedge funds.

Amgen stock opened at $189.08 on Wednesday. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12. The company has a market cap of $120.38 billion, a PE ratio of 15.03, a P/E/G ratio of 1.83 and a beta of 1.40.



Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The business had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. During the same quarter in the prior year, the business earned $3.27 earnings per share. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amgen, Inc. will post 14.02 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

AMGN has been the subject of several recent analyst reports. Cann restated a “buy” rating and set a $224.00 target price on shares of Amgen in a research note on Monday, October 1st. Royal Bank of Canada restated a “neutral” rating and set a $193.00 target price on shares of Amgen in a research note on Monday, September 10th. Oppenheimer restated a “buy” rating and set a $224.00 target price on shares of Amgen in a research note on Tuesday, August 28th. Jefferies Financial Group set a $220.00 target price on Amgen and gave the stock a “buy” rating in a research note on Wednesday, September 12th. Finally, Goldman Sachs Group restated a “buy” rating and set a $229.00 target price on shares of Amgen in a research note on Friday, October 12th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $205.16.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Article: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply